Almost ten years ago, Merck ushered superstar cancer drug Keytruda across the FDA finish line for the first time, opening the ...

After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that ...

With the two positive trials, GSK plans to file Blenrep with the FDA in the second half of this year, Hesham Abdullah, M.D., ...

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy ...

In the span of half a year, Gilead’s Trodelvy has flopped a second phase 3 trial. | Following a high-profile lung cancer ...

After Amgen’s KRAS confirmatory trial results were rejected by the FDA as uninterpretable, Bristol Myers Squibb has provided ...

Moderna's mRESVIA has secured FDA approval to protect adults ages 60 years and older from lower respiratory tract disease ...

While Canada’s largest vaccine manufacturing facility has opened its doors and is flying the Sanofi flag, another of the ...

With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much ...

One of the biggest take-aways from our report is that LGBTQ+ people are probably at higher risk for cancer, yet experience ...

In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of ...

Pfizer chalked up a key win in its legal battle surrounding the now-recalled smoking cessation drug Chantix after a New York ...